Rituximab is a monoclonal antibody currently being investigated as a potential therapy for MS. It is an approved treatment for various types of blood cancer and is marketed under the name Rituxan in the U.S. and MabThera in Europe. It is currently used off-label for MS. A Phase 3 trial in relapsing-remitting MS is ongoing.
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go …
Read moreResearchers at Johns Hopkins University in Baltimore presented key findings today, Feb. 19, concerning the presence of contrast-enhancing lesions in later stages in the relapsing-remitting experimental autoimmune encephalitis (EAE) model. The presentation was made at the Americas Committee for Treatment…
The Multiple Sclerosis Society of Canada recently published a report documenting and summarizing the most important developments in multiple sclerosis (MS) research during 2015. In early 2015, a Society-funded clinical trial was initiated to study the potential abilities of mesenchymal…
https://www.youtube.com/watch?v=ary4eEkIA6k In this video from MommyGeeksOut, follow her in one of her MS Diaries and learn how Mommy Started on Rituximab Treatment for Multiple Sclerosis. “After having to stop Tysabri treatments last fall because I test positive for the JC virus…
Neuromyelitis optica (NMO), a rare autoimmune disorder often mistaken for multiple sclerosis, is similar in that it is characterized by myelin destruction in the optic nerves and spinal cord. In contrast to multiple sclerosis, as reported by the…
Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.
Get regular updates to your inbox.